Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC)

Category Primary study
JournalJournal of Clinical Oncology
Year 2011
This article has no abstract
Epistemonikos ID: 3c612f31d9ba36fbec7a0b1570729c4217e0a9ff
First added on: Feb 04, 2025